SBB-PS0008-M0022 mgCHF 157.00
20S Immunoproteasome vs. 20S Constitutive Proteasome Activity: Ac-WLA-AMC exhibits a high specific activity and preference for 20S immunoproteasome compared to constitutive 20S proteasome.
|Purity Chemicals||≥99% (HPLC)|
|Solubility||Soluble in DMSO.|
|Declaration||Manufactured by South Bay Bio.|
|Other Product Data||
Use: After preparing a stock solution in DMSO (≥10mM) store product at -20°C to -80°C. It is recommended to make multiple aliquots after the first thaw to ensure best performance. Chymotrypsin-like activity can be measured using a typical working concentration range from 10-50µM.
Click here for a Typical Lot-specific Product Datasheet from the Original Manufacturer
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Protect from light.
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
Ac-WLA-AMC is a fluorogenic peptid substrate for measuring chymotrypsin-like activity of the proteasome. Hydrolysis of this substrate by the β5-subunit of the 20S proteasome is monitored by observing fluorescence at an Excitation wavelength of 345nm and Emission at 445nm. This substrate is specific to the constitutive proteasome and is not hydrolyzed efficiently by the immunoproteasome. 20S Proteasome enzyme requires activation with 0.035% SDS in the assay buffer.
- Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit: C. Blackburn, et al.; Biochem. J. 430, 461 (2010)
- The immunoproteasome as a therapeutic target for hematological malignancies: Z. Miller, et al.; Curr. Can. Drug Targets 14, 537 (2014)
- Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases: R. Ettari, et al.; Curr. Med. Chem. 23, 1217 (2016)